– USA, MA – Beta Bionics, Inc., a clinical-stage medical technology company today announced the appointment of Dr. Ed Damiano, President, CEO and co-founder to the new role of Executive Chair.
Martha Goldberg Aronson, Chair of the Board, is now serving as interim CEO while Beta Bionics conducts an external search for a new CEO.
Goldberg Aronson remains on the Board and Christy Jones is now serving as the Lead Independent Director of the Board.
In his role as Founder and Executive Chair, Damiano will focus on product pipeline and new-technology development, advancing clinical research programs, including the Bihormonal Bionic Pancreas Pivotal Trial, regulatory submissions and interactions with regulatory authorities, and preparation of scientific manuscripts for the primary literature. He will also remain a champion for the Beta Bionics public benefit mission and will continue to communicate that mission to the principal Beta Bionics stakeholders, including the diabetes community and the Beta Bionics employees and shareholders.
“The locking of the database for the Insulin-Only Bionic Pancreas Pivotal Trial and the additional financing that we recently received were watershed moments for us at Beta Bionics,” said Dr. Damiano. “These milestones are transformational for the organization as a whole, and have important implications for me personally, as I focus my expertise and skill sets on those tasks that best support the company going forward. The last year saw enormous growth for Beta Bionics and strong additions to our senior leadership team in Marcie Cain, our Chief People Officer, and Michael Pereira, our Chief Operating Officer. I look forward to working with Martha and the rest of the Board as we transition from the R&D and clinical-stage company we are today to the commercial-stage organization we aspire to be.”
As interim CEO and Board Director, Goldberg Aronson will be working with Damiano and the Board of Directors through the ongoing CEO search. Goldberg Aronson has spent her career in the medical device industry and has led global healthcare businesses ranging in size from incubation to $1 billion in revenue.
“I am excited to work with Ed in his role as Founder and Executive Chair,” said Goldberg Aronson. “This team of passionate, dedicated employees is well-positioned to take this company to the next phase of growth. As we prepare for commercialization, we remain committed to fulfilling the Beta Bionics public benefit mission.”
About Beta Bionics
Beta Bionics is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control.
Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.
For more information : https://www.betabionics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.